• Incidence of Adverse Events During Cereset Research Office Intervention [ Time Frame: 4 months ]
  Tolerability will be determined with adverse event monitoring and assessment of adverse events at visits 1, 2, 3, and 4 during Cereset Research Office Intervention using the CTCAE 5.0 (Grade 1-5, 1 = mild, 5 = death). Adverse events will be divided into four categories (common adverse events >15-20%, uncommon adverse events <15%, rare but potentially serious adverse events and unexpected toxicities).
• Incidence of Adverse Events During Cereset Research Wearable [ Time Frame: 4 months ]
  Tolerability will be determined with adverse event monitoring and assessment of adverse events bi-weekly during Cereset Research Wearable using the CTCAE 5.0 (Grade 1-5, 1 = mild, 5 = death). Adverse events will be divided into four categories (common adverse events >15-20%, uncommon adverse events <15%, rare but potentially serious adverse events and unexpected toxicities).
• Caregiver Interview [ Time Frame: 4 months ]
  Caregiver interview is a 21-item questionnaire that contains things a person might do when caring for a loved one with cancer. Scores ranges from 1-9 ('1' would state that the participant is not-at-all confident to accomplish the listed behavior; '9' would state that the participant is totally confident to accomplish the listed behavior. Numbers in the middle of the scale indicate that the participant is moderately confident to accomplish the listed behavior).
• Generalized Anxiety Disorder 7-item scale (GAD-7) [ Time Frame: 4 months ]
  The Generalized Anxiety Disorder-7 is a validated, short seven item scale. Response scale = (not at all sure = 0; several days = 1; over half the days = 2; to nearly every day = 3). Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
• Insomnia Severity Index (ISI) [ Time Frame: 4 months ]
  The Insomnia Severity Index is a validated, 7 item self-report questionnaire assessing the nature, severity, and impact of insomnia in the past month. Rating scale (0 = very satisfied to 4 = very dissatisfied; 0 = not at all noticeable to 4 = very much noticeable; 0 = not at all worried to 4 = very much worried; 0 = not at all interfering to 4 = very much interfering).
• Perceived Stress Scale Questionnaire [ Time Frame: 4 months ]
  The Perceived Stress Scale (PSS) is a 10-item psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Scale range is 0 = never, 4 = very often.
• Collection of Biometric (BIOPAC) Data - Blood Pressure [ Time Frame: 4 months ]
  Continuous readings of systolic blood pressures will be acquired from finger arterial pressure measurements for a minimum of 10 minutes for physiologic changes in heart rate variability and baroreflex sensitivity at pre-intervention (B1) and during, and post-intervention time points (B2, B3). The recordings of systolic blood pressures will be analyzed for calculation of multiple standard measures of HRV including the standard deviation of normal to normal intervals (SDNN), and the root mean square of successive beat-to-beat differences in R-R interval duration (rMSSD).
• Collection of Biometric (BIOPAC) Data - Heart Rate [ Time Frame: 4 months ]
  Continuous readings of heart rate will be acquired from electrocardiogram for a minimum of 10 minutes for physiologic changes in heart rate variability and baroreflex sensitivity at pre-intervention (B1) and during, and post-intervention time points (B2, B3). The recordings of heart rate will be analyzed for calculation of multiple standard measures of heart rate variability including the standard deviation of normal to normal intervals (SDNN), and the root mean square of successive beat-to-beat differences in R-R interval duration (rMSSD) .

Primary Objective:

• To determine the feasibility of completing the prescribed Cereset Research Office intervention for trial participants in this single arm, open label study.

Secondary Objectives

• To assess the tolerability of the intervention
• To assess changes in trial participant wellbeing and quality of life.
• To assess changes in physiological response at pre-intervention and post-intervention time points.

Exploratory Objectives

• To assess the utilization of Cereset Research Wearable (portable, limited scope wearable device) after the CRO intervention.
• To assess the participant acceptability of the Cereset Research Intervention.

• Device: Cereset Research Wearable
  Cereset Research Wearable is a portable, wearable
• Procedure: Stress management therapy
  Undergo Cereset research office intervention
• Other: Questionnaire administration
  Ancillary studies
• Other: Quality of Life Assessment
  Ancillary studies

Inclusion Criteria:

• ≥18 years of age
• Identified as caregiver by patient with high grade glioma as defined as the primary, non-professional, non-paid person who provides the majority of emotional financial and/or physical support. There will only be one trial participant allowed per patient/caregiver dyad.
• The trial participant must be caring for a patient who is:
• ≥18 years of age
• Has a histologically confirmed malignancy that is a high grade glioma which includes
• World Health Organization (WHO) grade IV glioma
• WHO grade III glioma
• WHO grade II glioma, isocitrate dehydrogenase wildtype (molecular glioblastoma multiforme)
• Patient with high grade glioma who are planning or are in the process of receiving at least >20 fractions of radiation therapy delivered at Wake Forest Baptist Medical Center Department of Radiation Oncology in Winston-Salem, NC.
• Trial participant is able to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).
• Trial participant is able to sit in a chair for 90 minutes.

Exclusion Criteria:

• Participant is a heavy alcohol user per the Substance Abuse and Mental Health Services Administration.
• Heavy alcohol use is defined as binge drinking on 5 or more days in the past month.
• Binge drinking is defined as 4 drinks for women and 5 drinks for men on the same occasion.
• Participant is caring for a patient who has previously completed 50% or more of adjuvant radiation therapy for high grade glioma defined as 50% or more of the total prescribed fractions delivered.
• Participant has severe hearing impairment defined as word discrimination at <50% with or without the use of hearing aids.
• Participant's weight is greater than or equal to 285 pounds at time of enrollment (chair limit).
• Prior participant use of transcranial magnetic stimulation (TMS), transcranial direct current stimulation (TDCS), alpha stimulation, neurofeedback, biofeedback, or deep brain stimulation (DBS) within one month before enrollment.
• Participant has previously used HIRREM, or Cereset.
• Participant has a known seizure disorder requiring ongoing anti-epileptics prescribed specifically for seizure disorder.
• Participant states he or she will not be able to abstain from daily use of alcohol or recreational drugs during the intervention period.